Concepedia

Elisabeth Knauth

EK

Statistics

Publications

5

Citations

445

H-Index

5

Active since

2002

Affiliations

Pfizer (United States)(Current)

Elisabeth Knauth is an author at Pfizer (United States) specializing in pharmacology, drug discovery, and potency optimization.

Publications per year

2002–2008

5

Publications

5

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Jean S. Beebe, Jitesh P. Jani, Elisabeth Knauth et al. · PubMed · 2003 · 128 citations

, , +16

Evidence for the epidermal growth factor receptor as a target for lung cancer prevention.

Fulvio Lonardo, Konstantin H. Dragnev, Sarah J. Freemantle et al. · PubMed · 2002 · 98 citations

, , +14

Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity

Michael J. Munchhof, Jean S. Beebe, Jeffery M. Casavant et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 96 citations · Full text

, , +12

Synthesis and structure based optimization of novel Akt inhibitors

Blaise Lippa, Gonghua Pan, Matthew S. Corbett et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 76 citations · Full text

, , +12

Discovery of novel isothiazole inhibitors of the TrkA kinase: Structure–activity relationship, computer modeling, optimization, and identification of highly potent antagonists

Blaise Lippa, Joel Morris, Matthew S. Corbett et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 47 citations · Full text

, , +16

1–5 of 5